$ 27.05
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis,...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of VKTX is 84 and suggests 211% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
